Delusional misidentification syndromes (DMS) are neuropsychiatric conditions in which a person wrongly believes that people, places, or living beings are not what they appear to be. When the belief centers on another person being a “fake human” (or impostor-like), clinicians consider syndromes such as Capgras syndrome, where a familiar individual is perceived as an imposter despite intact face recognition. Related entities include Fregoli syndrome (belief that different people are actually the same person in disguise) and subjective doubles (belief that one’s likeness exists as an independent being). These phenomena are not mere oddities; they are structured, persistent delusional beliefs that cause distress and can affect behavior, safety, and relationships.
Core clinical features typically include (1) a specific misidentification belief, (2) relative preservation of basic perceptual abilities (the person can recognize faces as familiar, yet the emotional or identity link feels incorrect), (3) delusional certainty that resists counterevidence, and (4) functional impairment or distress. Unlike typical misinterpretations, DMS is characterized by a stable explanatory framework for why the mismatch is occurring, often with high conviction.
Mechanistically, one influential model proposes a disconnect between ventral visual face processing and limbic/emotional attribution networks. In Capgras, the individual may correctly identify a face via ventral stream pathways but shows reduced physiological response (e.g., diminished autonomic “familiarity” signaling) because connections to emotional appraisal and fear circuits are disrupted. Neuroimaging and lesion studies have implicated pathways involving the fusiform gyrus, amygdala, anterior cingulate, and temporal–fronto-parietal networks. Functional dysregulation can occur without a focal stroke, including in neurodegenerative disease, epilepsy, autoimmune encephalitis, schizophrenia-spectrum disorders, and after intoxication or withdrawal.
DMS can be primary (associated with a primary psychiatric syndrome) or secondary (resulting from neurologic disease or systemic conditions). Secondary causes matter because treatment depends on the driver. Common secondary associations include Parkinson’s disease and dementia with Lewy bodies, where misperceptions may coexist with hallucinations and cognitive fluctuation; Alzheimer’s disease and other dementias; traumatic brain injury; temporal lobe epilepsy (including post-ictal psychosis); and medication or substance effects such as anticholinergics, stimulants, corticosteroids, cannabis withdrawal, and alcohol withdrawal.
In differential diagnosis, clinicians separate DMS from (1) hallucinations without delusional interpretation, (2) illusion-like errors driven by sensory impairment, (3) psychosis with broad, systematized paranoia, (4) cognitive distortions from severe delirium, and (5) specific identity confusion due to intoxication or sleep deprivation. A careful assessment of onset timing, neurologic symptoms (headache, seizures, focal deficits), cognitive status, medication history, and substance use is essential.
Evaluation usually includes a mental status exam, cognitive screening, and review of medical history. Laboratory testing may include metabolic panels, thyroid function, vitamin B12/folate, infectious or autoimmune screening when indicated, and toxicology for suspected substance-related causes. Brain MRI or CT is considered when there are neurologic red flags, new onset, atypical progression, or concern for structural lesions. EEG may be warranted if seizures are possible.
Treatment has two parallel aims: address the underlying condition and reduce delusional distress. When a secondary etiology is identified, correcting it (e.g., antiseizure therapy for epilepsy, immunotherapy for autoimmune encephalitis, adjustment of offending medications, or delirium management) can substantially improve beliefs. For persistent delusions, antipsychotic medication is often used, tailored to patient age, comorbidities, and side-effect risk; some cases respond to atypical antipsychotics such as risperidone or olanzapine, though evidence is largely based on case series and clinical experience. For certain presentations with comorbid mood or obsessive features, antidepressants or mood stabilizers may be considered. Psychosocial interventions emphasize grounding, reducing reinforcement of the delusion, improving reality-based communication, and supporting caregivers.
A key principle is that confrontation can backfire. Therapeutic strategies tend to validate distress without endorsing the delusion, for example by acknowledging that the person feels something is fundamentally wrong while gently exploring alternative explanations. If safety is at risk—such as threats of harm toward the alleged “imposter”—urgent psychiatric evaluation is required.
Prognosis depends on cause, duration, and comorbidity. DMS associated with reversible delirium or medication effects may improve after correction. DMS linked to neurodegenerative disease can become chronic but may still respond partially to targeted psychiatric treatment and caregiver strategies. Early recognition is clinically important because it guides diagnostic workup and prevents misattribution of symptoms solely to character or willpower.
If someone reports a persistent “fake person” belief, clinicians should consider delusional misidentification as a specific neuropsychiatric framework and evaluate for neurologic, medication, or psychiatric causes. This approach improves diagnostic accuracy, informs safer treatment, and helps reduce the isolation and escalation that can accompany high-certainty delusional thinking. Source: [@scrounger_42809 / Source Link: x.com/scrounger_42809/status/2067853279300579694]
The Scrounger: @TheLastHopeUSA Fake Human Alert!. #breaking
— @scrounger_42809 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
